Search - tctmd.com

Displaying 681 - 693 of 693

Sort: Relevancy | Date

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

June 16, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

June 02, 2015

News Industry News

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

May 26, 2015

News Industry News

CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference

May 26, 2015

News Industry News

Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

May 22, 2015

Presentation CATCH-UP 2015

Advances in Heart Failure Therapy: PARADIGM-HF

Presenter: Mat Maurer

April 25, 2015

Presentation CATCH-UP 2015

Preventing Heart Failure Readmissions in the Era of Health Care Reform

Presenter: Susan Woodley

April 24, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

Todd Neale

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

Todd Neale

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

Evaluating the Heart Failure Patient with MR: Integrating Train Data Into Clinical Practice

CME

Advertisement

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Juventas Therapeutics Granted FDA Fast Track Designation and Phase 2b Protocol Allowance for Novel Heart Failure Gene Therapy

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

Juventas Therapeutics Presents New 12-Month Data Demonstrating Single Administration of JVS-100 Improves Cardiac and Clinical Status in Patients with Severe Ischemic Heart Failure One Year After Treat

CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference

Cardiorentis Completes Enrollment in Pivotal Phase III Clinical Trial of Ularitide for Acute Heart Failure

Advances in Heart Failure Therapy: PARADIGM-HF

Preventing Heart Failure Readmissions in the Era of Health Care Reform

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Evaluating the Heart Failure Patient with MR: Integrating Data Into Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content